EP Patent

EP2601212A1 — Methods and compounds for the diagnosis and treatment of

Assigned to Cizzle Biotechnology Ltd · Expires 2013-06-12 · 13y expired

What this patent protects

The present invention provides for methods for use in the diagnosis and prognosis of cancer. The invention further provides to binding agents and kits for us e.g., in such methods. The present invention further relates to compositions, methods of making said compositions and meth…

USPTO Abstract

The present invention provides for methods for use in the diagnosis and prognosis of cancer. The invention further provides to binding agents and kits for us e.g., in such methods. The present invention further relates to compositions, methods of making said compositions and methods of using the same, including use in the treatment and diagnosis of cancer, including lung, lymphoma, liver, thyroid and bladder cancer. Compositions of the present invention useful in the treatment of cancer include antisense and small inhibitory RNAs (siRNA).

Drugs covered by this patent

Patent Metadata

Patent number
EP2601212A1
Jurisdiction
EP
Classification
Expires
2013-06-12
Drug substance claim
No
Drug product claim
No
Assignee
Cizzle Biotechnology Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.